{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T01:58:21Z","timestamp":1792979901927,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T00:00:00Z","timestamp":1757548800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005847","name":"Health and Medical Research Fund","doi-asserted-by":"crossref","award":["22210062"],"award-info":[{"award-number":["22210062"]}],"id":[{"id":"10.13039\/501100005847","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1007\/s40121-025-01225-z","type":"journal-article","created":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T02:33:26Z","timestamp":1757558006000},"page":"2445-2463","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Cardiovascular Safety of COVID-19 Treatments: A Disproportionality Analysis of Adverse Event Reports from the WHO VigiBase"],"prefix":"10.1007","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0409-5930","authenticated-orcid":false,"given":"Hoi K.","family":"Cheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5262-661X","authenticated-orcid":false,"given":"Angel","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5920-9341","authenticated-orcid":false,"given":"Maxwell","family":"Kwok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0430-5752","authenticated-orcid":false,"given":"Bryan P.","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9280-3681","authenticated-orcid":false,"given":"Ellen Ngar-Yun","family":"Poon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,11]]},"reference":[{"issue":"2","key":"1225_CR1","doi-asserted-by":"publisher","first-page":"e0011923","DOI":"10.1128\/cmr.00119-23","volume":"37","author":"D Focosi","year":"2024","unstructured":"Focosi D, Franchini M, Maggi F, Shoham S. COVID-19 therapeutics. Clin Microbiol Rev. 2024;37(2):e0011923.","journal-title":"Clin Microbiol Rev"},{"issue":"1","key":"1225_CR2","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41392-022-01249-8","volume":"7","author":"S Lei","year":"2022","unstructured":"Lei S, Chen X, Wu J, Duan X, Men K. Small molecules in the treatment of COVID-19. Signal Transduct Target Ther. 2022;7(1):387.","journal-title":"Signal Transduct Target Ther"},{"issue":"3","key":"1225_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2020.107940","volume":"32","author":"AJ Pruijssers","year":"2020","unstructured":"Pruijssers AJ, George AS, Schafer A, Leist SR, Gralinksi LE, Dinnon KH 3rd, et al. Remdesivir inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice. Cell Rep. 2020;32(3): 107940.","journal-title":"Cell Rep"},{"issue":"6","key":"1225_CR4","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa2116044","volume":"386","author":"A Jayk Bernal","year":"2022","unstructured":"Jayk Bernal A, Gomes da Silva MM, Musungaie DB, Kovalchuk E, Gonzalez A, Delos Reyes V, et al. Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients. N Engl J Med. 2022;386(6):509\u201320.","journal-title":"N Engl J Med"},{"key":"1225_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","volume":"54","author":"VJ Costela-Ruiz","year":"2020","unstructured":"Costela-Ruiz VJ, Illescas-Montes R, Puerta-Puerta JM, Ruiz C, Melguizo-Rodriguez L. SARS-CoV-2 infection: the role of cytokines in COVID-19 disease. Cytokine Growth Factor Rev. 2020;54:62\u201375.","journal-title":"Cytokine Growth Factor Rev"},{"issue":"23","key":"1225_CR6","first-page":"2281","volume":"327","author":"R Rubin","year":"2022","unstructured":"Rubin R. Baricitinib is first approved COVID-19 immunomodulatory treatment. JAMA. 2022;327(23):2281.","journal-title":"JAMA"},{"issue":"7","key":"1225_CR7","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1136\/annrheumdis-2019-215987","volume":"79","author":"IH Shafran","year":"2020","unstructured":"Shafran IH, Alasti F, Smolen JS, Aletaha D. Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. Ann Rheum Dis. 2020;79(7):874\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"1225_CR8","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.tips.2011.07.007","volume":"32","author":"N Apostolova","year":"2011","unstructured":"Apostolova N, Blas-Garcia A, Esplugues JV. Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-gamma inhibition. Trends Pharmacol Sci. 2011;32(12):715\u201325.","journal-title":"Trends Pharmacol Sci"},{"issue":"4","key":"1225_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100052","volume":"1","author":"A Sharma","year":"2020","unstructured":"Sharma A, Garcia G Jr., Wang Y, Plummer JT, Morizono K, Arumugaswami V, et al. Human iPSC-derived cardiomyocytes are susceptible to SARS-CoV-2 infection. Cell Rep Med. 2020;1(4): 100052.","journal-title":"Cell Rep Med"},{"issue":"2","key":"1225_CR10","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1136\/ard-2022-223050","volume":"82","author":"V Molander","year":"2023","unstructured":"Molander V, Bower H, Frisell T, Delcoigne B, Di Giuseppe D, Askling J, et al. Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis. Ann Rheum Dis. 2023;82(2):189\u201397.","journal-title":"Ann Rheum Dis"},{"key":"1225_CR11","doi-asserted-by":"publisher","DOI":"10.3390\/ph15121472","author":"J Zou","year":"2022","unstructured":"Zou J, Jing F. Cardiovascular adverse events associated with monoclonal antibody products in patients with COVID-19. Pharmaceuticals (Basel). 2022. https:\/\/doi.org\/10.3390\/ph15121472.","journal-title":"Pharmaceuticals (Basel)"},{"key":"1225_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/2041-1480-5-36","volume":"5","author":"L Wang","year":"2014","unstructured":"Wang L, Jiang G, Li D, Liu H. Standardizing adverse drug event reporting data. J Biomed Semant. 2014;5: 36.","journal-title":"J Biomed Semant"},{"issue":"5","key":"1225_CR13","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist M. Vigibase, the WHO global ICSR database system: basic facts. Drug Inf J DIJ\/Drug Inf Assoc. 2008;42(5):409\u201319.","journal-title":"Drug Inf J DIJ\/Drug Inf Assoc"},{"key":"1225_CR14","unstructured":"Uppsala Monitoring Centre. VigiBase, WHO\u2019s global database 2024. https:\/\/who-umc.org\/vigibase\/vigibase-who-s-global-database\/."},{"issue":"7","key":"1225_CR15","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1002\/jmv.27697","volume":"94","author":"S Chenchula","year":"2022","unstructured":"Chenchula S, Karunakaran P, Sharma S, Chavan M. Current evidence on efficacy of COVID-19 booster dose vaccination against the Omicron variant: a systematic review. J Med Virol. 2022;94(7):2969\u201376.","journal-title":"J Med Virol"},{"key":"1225_CR16","unstructured":"Uppsala Monitoring Centre. Guideline for using VigiBase data in studies. 2021."},{"issue":"7","key":"1225_CR17","doi-asserted-by":"publisher","first-page":"3535","DOI":"10.1111\/bcp.15269","volume":"88","author":"E Raschi","year":"2022","unstructured":"Raschi E, Salvo F, Khouri C. Conceiving, conducting, reporting, interpreting, and publishing disproportionality analyses: a call to action. Br J Clin Pharmacol. 2022;88(7):3535\u20136.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"1225_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Noren","year":"2013","unstructured":"Noren GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22(1):57\u201369.","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"1225_CR19","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","volume":"54","author":"A Bate","year":"1998","unstructured":"Bate A, Lindquist M, Edwards IR, Olsson S, Orre R, Lansner A, et al. A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol. 1998;54(4):315\u201321.","journal-title":"Eur J Clin Pharmacol"},{"key":"1225_CR20","doi-asserted-by":"publisher","DOI":"10.2196\/43906","volume":"4","author":"SR Khetran","year":"2023","unstructured":"Khetran SR, Mustafa R. Mutations of SARS-CoV-2 structural proteins in the Alpha, Beta, Gamma, and Delta variants: bioinformatics analysis. JMIR Bioinform Biotechnol. 2023;4: e43906.","journal-title":"JMIR Bioinform Biotechnol"},{"key":"1225_CR21","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment May 01, 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-issues-emergency-use-authorization-potential-covid-19-treatment."},{"issue":"27","key":"1225_CR22","doi-asserted-by":"publisher","first-page":"2598","DOI":"10.1056\/NEJMp2032369","volume":"383","author":"D Rubin","year":"2020","unstructured":"Rubin D, Chan-Tack K, Farley J, Sherwat A. FDA approval of remdesivir\u2014a step in the right direction. N Engl J Med. 2020;383(27):2598\u2013600.","journal-title":"N Engl J Med"},{"key":"1225_CR23","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Drug Combination for Treatment of COVID-19 November 19. 2020. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-combination-treatment-covid-19."},{"key":"1225_CR24","unstructured":"U.S. Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes Drug for Treatment of COVID-19 June 24, 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-drug-treatment-covid-19."},{"issue":"2","key":"1225_CR25","doi-asserted-by":"publisher","DOI":"10.4110\/in.2023.23.e13","volume":"23","author":"BT Padasas","year":"2023","unstructured":"Padasas BT, Espano E, Kim SH, Song Y, Lee CK, Kim JK. COVID-19 therapeutics: an update on effective treatments against infection with SARS-CoV-2 variants. Immune Netw. 2023;23(2): e13.","journal-title":"Immune Netw"},{"key":"1225_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s10557-024-07570-4","author":"J Gu","year":"2024","unstructured":"Gu J, Han ZH, Wang CQ, Zhang JF. The impacts of nirmatrelvir-ritonavir on myocardial injury and long-term cardiovascular outcomes in hospitalized patients with COVID-19 amid the Omicron wave of the pandemic. Cardiovasc Drugs Ther. 2024. https:\/\/doi.org\/10.1007\/s10557-024-07570-4.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"1","key":"1225_CR27","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12916-024-03331-0","volume":"22","author":"W Wang","year":"2024","unstructured":"Wang W, Wang YH, Huang CH, Hsieh TH, Ibarburu GH, Wei JC. Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study. BMC Med. 2024;22(1):117.","journal-title":"BMC Med"},{"key":"1225_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/2050313X231168304","volume":"11","author":"E DeMarco","year":"2023","unstructured":"DeMarco E, Turnipseed M, Clarke B, Qadeer F. Possible nirmatrelvir\/ritonavir-induced bradycardia in a patient with asymptomatic COVID-19. SAGE Open Med Case Rep. 2023;11: 2050313X231168304.","journal-title":"SAGE Open Med Case Rep"},{"issue":"1","key":"1225_CR29","first-page":"e33831","volume":"15","author":"VM Ganipisetti","year":"2023","unstructured":"Ganipisetti VM, Bollimunta P, Maringanti S. Paxlovid-induced symptomatic bradycardia and syncope. Cureus. 2023;15(1):e33831.","journal-title":"Cureus"},{"key":"1225_CR30","doi-asserted-by":"publisher","first-page":"1253799","DOI":"10.3389\/fphar.2023.1253799","volume":"14","author":"Y Liang","year":"2023","unstructured":"Liang Y, Ma L, Wang Y, Zheng J, Su L, Lyu J. Adverse events associated with molnupiravir: a real-world disproportionality analysis in the Food and Drug Administration Adverse Event Reporting System. Front Pharmacol. 2023;14:1253799.","journal-title":"Front Pharmacol"},{"issue":"1","key":"1225_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3390\/jcm12010034","volume":"12","author":"G Santi Laurini","year":"2022","unstructured":"Santi Laurini G, Montanaro N, Motola D. Safety profile of molnupiravir in the treatment of COVID-19: a descriptive study based on FAERS data. J Clin Med. 2022;12(1):34.","journal-title":"J Clin Med"},{"key":"1225_CR32","unstructured":"World Health Organization. Therapeutics and COVID-19: living guideline. Geneva; 2023 10 November. Report No.: WHO\/2019-nCoV\/clinical\/2023.2."},{"key":"1225_CR33","unstructured":"U.S. Food and Drug Administration. Fact Sheet for Patients and Caregivers: Emergency Use Authorization (EUA) of LAGEVRIO\u2122 (molnupiravir) capsules for Coronavirus Disease 2019 (COVID-19) 2024. https:\/\/www.fda.gov\/media\/155055\/download. Accessed June 2024."},{"issue":"2","key":"1225_CR34","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1093\/cid\/ciae170","volume":"79","author":"V Terzic","year":"2024","unstructured":"Terzic V, Miantezila Basilua J, Billard N, de Gastines L, Belhadi D, Fougerou-Leurent C, et al. Cardiac adverse events and remdesivir in hospitalized patients with COVID-19: a post hoc safety analysis of the randomized DisCoVeRy Trial. Clin Infect Dis. 2024;79(2):382\u201391.","journal-title":"Clin Infect Dis"},{"key":"1225_CR35","doi-asserted-by":"publisher","first-page":"1106044","DOI":"10.3389\/fphar.2023.1106044","volume":"14","author":"YS Alsowaida","year":"2023","unstructured":"Alsowaida YS, Shehadeh F, Kalligeros M, Mylonakis E. Incidence and potential risk factors for remdesivir-associated bradycardia in hospitalized patients with COVID-19: a retrospective cohort study. Front Pharmacol. 2023;14:1106044.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1225_CR36","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1111\/cts.13168","volume":"15","author":"SY Jung","year":"2022","unstructured":"Jung SY, Kim MS, Li H, Lee KH, Koyanagi A, Solmi M, et al. Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database. Clin Transl Sci. 2022;15(2):501\u201313.","journal-title":"Clin Transl Sci"},{"issue":"3","key":"1225_CR37","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1007\/s12012-021-09703-9","volume":"22","author":"M Nabati","year":"2022","unstructured":"Nabati M, Parsaee H. Potential cardiotoxic effects of remdesivir on cardiovascular system: a literature review. Cardiovasc Toxicol. 2022;22(3):268\u201372.","journal-title":"Cardiovasc Toxicol"},{"key":"1225_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104955","volume":"184","author":"SW Choi","year":"2020","unstructured":"Choi SW, Shin JS, Park SJ, Jung E, Park YG, Lee J, et al. Antiviral activity and safety of remdesivir against SARS-CoV-2 infection in human pluripotent stem cell-derived cardiomyocytes. Antivir Res. 2020;184: 104955.","journal-title":"Antivir Res"},{"issue":"1","key":"1225_CR39","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s13578-024-01280-y","volume":"14","author":"BW Mok","year":"2024","unstructured":"Mok BW, Kwok M, Li HS, Ling L, Lai A, Yan B, et al. SARS-CoV-2 variants divergently infect and damage cardiomyocytes in vitro and in vivo. Cell Biosci. 2024;14(1):101.","journal-title":"Cell Biosci"},{"issue":"12","key":"1225_CR40","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","volume":"9","author":"VC Marconi","year":"2021","unstructured":"Marconi VC, Ramanan AV, de Bono S, Kartman CE, Krishnan V, Liao R, et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir Med. 2021;9(12):1407\u201318.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"1225_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-023-01403-0","volume":"28","author":"J Sun","year":"2023","unstructured":"Sun J, Wang S, Ma X, Wei Q, Peng Y, Bai Y, et al. Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis. Eur J Med Res. 2023;28(1): 536.","journal-title":"Eur J Med Res"},{"key":"1225_CR42","doi-asserted-by":"publisher","first-page":"5535486","DOI":"10.1155\/2021\/5535486","volume":"2021","author":"T Alsulaim","year":"2021","unstructured":"Alsulaim T, Alhassan N, Khalil H, Almutlaq A. Tocilizumab effect on lipid profile in correlation to cardiovascular events: a retrospective cohort study. Int J Rheumatol. 2021;2021:5535486.","journal-title":"Int J Rheumatol"},{"issue":"1","key":"1225_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-53087-z","volume":"14","author":"O Aljuhani","year":"2024","unstructured":"Aljuhani O, Al Sulaiman K, Korayem GB, Altebainawi AF, Alsohimi S, Alqahtani R, et al. The association between tocilizumab therapy and the development of thrombosis in critically ill patients with COVID-19: a multicenter, cohort study. Sci Rep. 2024;14(1): 3037.","journal-title":"Sci Rep"},{"key":"1225_CR44","doi-asserted-by":"crossref","unstructured":"COVID-19 update: Tocilizumab (Actemra) FDA-approved for treatment of COVID-19. Med Lett Drugs Ther. 2023;65(1667):e9.","DOI":"10.58347\/tml.2023.1667d"},{"key":"1225_CR45","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2022-002236","author":"TW Kragstrup","year":"2022","unstructured":"Kragstrup TW, Glintborg B, Svensson AL, McMaster C, Robinson PC, Deleuran B, et al. Waiting for JAK inhibitor safety data. RMD Open. 2022. https:\/\/doi.org\/10.1136\/rmdopen-2022-002236.","journal-title":"RMD Open"},{"key":"1225_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052449","author":"PJ Kotyla","year":"2021","unstructured":"Kotyla PJ, Engelmann M, Giemza-Stok\u0142osa J, Wnuk B, Islam MA. Thromboembolic adverse drug reactions in Janus kinase (JAK) inhibitors: does the inhibitor specificity play a role? Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22052449.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"1225_CR47","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1161\/CIRCULATIONAHA.122.060785","volume":"146","author":"R Knight","year":"2022","unstructured":"Knight R, Walker V, Ip S, Cooper JA, Bolton T, Keene S, et al. Association of COVID-19 with major arterial and venous thrombotic diseases: a population-wide cohort study of 48 million adults in England and Wales. Circulation. 2022;146(12):892\u2013906.","journal-title":"Circulation"},{"issue":"7902","key":"1225_CR48","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-022-04442-5","volume":"603","author":"H Shuai","year":"2022","unstructured":"Shuai H, Chan JF, Hu B, Chai Y, Yuen TT, Yin F, et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. 2022;603(7902):693\u20139.","journal-title":"Nature"},{"issue":"11","key":"1225_CR49","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1161\/ATVBAHA.124.321001","volume":"44","author":"JR Hilser","year":"2024","unstructured":"Hilser JR, Spencer NJ, Afshari K, Gilliland FD, Hu H, Deb A, et al. COVID-19 is a coronary artery disease risk equivalent and exhibits a genetic interaction with ABO blood type. Arterioscler Thromb Vasc Biol. 2024;44(11):2321\u201333.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1225_CR50","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.cmi.2022.10.015","volume":"29","author":"T Karampitsakos","year":"2023","unstructured":"Karampitsakos T, Papaioannou O, Tsiri P, Katsaras M, Katsimpris A, Kalogeropoulos AP, et al. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial. Clin Microbiol Infect. 2023;29(3):372\u20138.","journal-title":"Clin Microbiol Infect"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01225-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01225-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01225-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T09:27:18Z","timestamp":1759138038000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01225-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,11]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1225"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01225-z","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,11]]},"assertion":[{"value":"23 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Hoi Ki Cheng is an employee of Pfizer Inc, but the latter did not play any role in the design and execution of this study. All other authors (Angel Lai, Maxwell Kwok, Bryan P Yan, Ellen N Poon) have no conflicts of interest relevant to the content of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article is based on available data in VigiBase (), and the data is anonymous and is available upon request from said database. This manuscript does not contain any new studies with human participants or animals performed by any of the authors. The study was approved by the ethics committee of The Chinese University of Hong Kong (CUHK) and New Territories East Cluster (NTEC) (Ref. No. 2023.186). Since only anonymous data was collected, informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}